No products in the cart.
Diagnostic hapten-carrier conjugates BSA-mycophenolic acid (MPA), OVA-mycophenolic acid (MPA), KLH-mycophenolic acid (MPA) for autoimmune diseaseMPA detection in Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
Cat:GMP-SMT-MPA-Ag
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Mycophenolic acid (MPA) is an immunosuppressant medication used to prevent rejection following organ transplantation and to treat autoimmune conditions such as Crohn’s disease and lupus. Specifically it is used following kidney, heart, and liver transplantation. It can be given by mouth or by injection into a vein. It comes as mycophenolate sodium and mycophenolate mofetil.Genemedi produces core diagnostic ingredients for test of autoimmune disease and related syndrome.
GeneMedi offers Diagnostic hapten-carrier conjugates BSA-mycophenolic?acid (MPA), OVA-mycophenolic?acid (MPA), KLH-mycophenolic?acid (MPA) for autoimmune disease MPA detection in Competitive immunoassay validation (Competitive ELISA), Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for autoimmune disease test are suitable for in functional ELISA, and other immunoassays in dignostics.
Product Description
|
Cat No.
|
GMP-SMT-MPA-Ag
|
|
Product Name
|
BSA-mycophenolic acid (MPA) / OVA-mycophenolic acid (MPA)
|
|
Expression platform
|
Synthetic
|
|
Bioactivity validation
|
mycophenolic acid (MPA) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in MPA level test of Inflammation/autoimmune/inflammatory disease (autoimmune disease) and related syndrome evaluation
|
|
Products description
|
Competitive immunoassay-validated hapten-carrier conjugates BSA-mycophenolic acid (MPA) / OVA-mycophenolic acid (MPA) is Synthetic.
|
|
Purity
|
|
|
Application
|
Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
|
|
Formulation
|
Lyophilized from sterile PBS, PH 7.4
|
|
Storage
|
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
|
|
Cat No.
|
GMP-SMT-MPA-Ag
|
|
Product Name
|
|
|
Expression platform
|
|
|
Isotypes
|
|
|
Bioactivity validation
|
|
|
Tag
|
|
|
Products description
|
|
|
Specics
|
|
|
Purity
|
|
|
Application
|
|
|
Formulation
|
|
|
Storage
|
|
Previous slide
Next slide
Diagnostic antibodies and antigens for Epilepsy-related valproate (VPA) toxicity testing: Sodium valproate (VPA)
Valproate is a commonly used antiepileptic drug for the treatment of epilepsy and seizures. It is safe for use in both adults and children more than three years of age. Valproate toxicity can occur both accidentally and intentionally. Acute valproate overdose usually presents with CNS depression/encephalopathy, electrolyte abnormalities such as hypernatremia, elevated transaminase levels, hyperammonemia, and hepatoxicity. In patients with a severe overdose of valproate, patients can present with hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related hyperammonemic encephalopathy which may progress to coma and death. GENEMEDI developed the Gastrin-17 (G-17) antigens and antibodies for the diagnosis of valproate toxicity based on ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
